Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.35 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28996866 | 0.85 | GPR84 (0.55) | GPR84TDP1ALDH1A1TSHRSLC22A6 | |
| SCHEMBL29144599 | 0.85 | CACNA2D1 (0.39) | GPR84ADRA1ATDP1CACNA2D1CACNB3 | |
| SCHEMBL27678641 | 0.82 | SLC22A6 (0.41) | ADRA1ATDP1CACNA2D1CACNB3CACNA1C | |
| SCHEMBL1335604 | 0.82 | ADRA1A (0.48) | GPR84ADRA1AHDAC1HDAC2TDP1 | |
| SCHEMBL967149 | 0.82 | ADRA1A (0.48) | GPR84ADRA1AHDAC1HDAC2TDP1 | |
| SCHEMBL7933234 | 0.82 | GPR84 (0.37) | GPR84ADRA1AHDAC1HDAC2TDP1 | |
| SCHEMBL8002550 | 0.82 | CHRM1 (0.32) | ADRA1AHDAC1HDAC2TDP1CHRM1 | |
| SCHEMBL11546916 | 0.81 | GSTK1 (0.36) | GPR84ADRA1ATDP1CACNA2D1CACNB3 | |
| SCHEMBL11294180 | 0.80 | ADRA1A (0.46) | GPR84ADRA1AHDAC1HDAC2TDP1 | |
| SCHEMBL3844336 | 0.79 | ALDH1A1 (0.38) | ADRA1AHDAC1HDAC2TDP1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100395234-C | Novel CB1 receptor inverse agonists | HOFFMANN LA ROCHE (CH) | 2008-06-18 | — | — | CN | disclosed |
| CN-101012193-A | Novel CB 1 receptour inverse agonists | HOFFMANN LA ROCHE (CH) | 2007-08-08 | — | — | CN | disclosed |
| US-20070010477-A1 | Acyl homoserine lactones for inhibition of cell growth | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-01-11 | — | — | US | disclosed |
| WO-2006110531-A2 | ACYL HOMOSERINE LACTONES FOR INHIBITION OF CELL GROWTH | HEALTH RESEARCH INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| CN-1735593-A | Novel CB1 receptor inverse agonists | HOFFMANN LA ROCHE (CH) | 2006-02-15 | — | — | CN | disclosed |
| CN-1321152-A | Substituted oxazole and thiazole derivatives as hPPAR gamma and hPPAR alpha activators | GLAXO GROUP LTD (GB) | 2001-11-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010477-A1 | Acyl homoserine lactones for inhibition of cell growth | AHCYL1, HCCS, ACSL1 | GPR84 2325/4885ADRA1A 4212/4885HDAC1 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.